Examination of the epidemiology investigation in the rheumatoid arthritis new onset patient

Examination of the epidemiology investigation in the rheumatoid arthritis new onset patient - Examination of the epidemiology investigation in the rheumatoid arthritis new onset patient

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025537

Enrollment

200

Registered

2017-01-06

Start date

2017-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with rheumatoid arthritis onset.

Exclusion criteria

Exclusion criteria: Patients with rheumatoid arthritis received some kind of treatments with DMARD.

Design outcomes

Primary

Measure	Time frame
Possession rate of antibodies and their titer, such as rheumatoid factor, anti-SSA/Ro antibody and anti- cyclic citrullinated peptide antibody in non-treatment after the rheumatoid arthritis onset. And possession rate of risk factors (ex; gender, smoking habit, periodontitis, bronchitis and interstitial pneumonitis) in conjunction with these antibody instructions.	—

Secondary

Measure	Time frame
Evaluation of the influence that antibodies and an antibody instruction risks give in an episode of care of the rheumatoid arthritis (as follows) 1) Disease activity scores (Week 0, 24, 52) 2) Functional assessment with HAQDI (week 0, 24, 52) 3) Radiographic assessment (Week 0, 24, 52) 4) Possession rates of bronchitis and interstitial penumonitis (Week 0, 52) with chest CT and measurement of vital capacity by a spirometer and flow-volume curve, carbon monoxide lung diffusing capacity.	—

Measure

Time frame

Evaluation of the influence that antibodies and an antibody instruction risks give in an episode of care of the rheumatoid arthritis (as follows) 1) Disease activity scores (Week 0, 24, 52) 2) Functional assessment with HAQDI (week 0, 24, 52) 3) Radiographic assessment (Week 0, 24, 52) 4) Possession rates of bronchitis and interstitial penumonitis (Week 0, 52) with chest CT and measurement of vital capacity by a spirometer and flow-volume curve, carbon monoxide lung diffusing capacity.

—

Countries

Japan

Contacts

Public ContactTakafumi Hagiwara

Takarazuka City Hospital Division of Rheumatology

thagiwara-college@umin.ac.jp0797-87-1161

Outcome results